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Abstract 
Homozygotes for homocystinuria due to cystathionine synthase (CS) deficiency accumulate homocysteine and methionine in their 
blood and tissues. High-dose pyridoxin, folic acid, vitamin B 12, or betaine are therapeutical options to lower the elevated homocysteine 
concentration. These compounds stimulate the transsulfuration or remethylation f homocysteine. Despite such treatment, elevated blood 
homocysteine concentrations may persist in many homocystinurics. Therefore, it is warranted to study alternative regimen to reduce the 
blood homocysteine concentration i  homocystinurics. Apart from entering the transsulfuration pathway, methionine can be catabolized 
via the transamination pathway, by conversion into 4-methylthio-2-oxobutyrate (MTOB), followed by oxidative decarboxylation f
MTOB to 3-methylthiopropionate. Thiamine pyrophosphate, the active form of thiamine, is a cofactor of the supposed rate-limiting 
oxidative decarboxylation in the transamination of methionine. The effect of thiamine administered in 2 or 3 daily doses of 25 mg orally, 
was studied in nine homozygote CS deficient patients. Methionine levels decreased in 6 out of 9 patients. In 8 out of 9 patients, however, 
the levels of plasma homocysteine r mained virtually unchanged, as did the serum transamination metabolites in all patients. We conclude 
that vitamin B I cannot be used as an additional homocysteine-lowering treatment in most homozygotes for homocystinuria. 
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1. Introduction 
Patients with classic homocystinuria due to cystathion- 
ine synthase (CS) deficiency accumulate homocysteine and 
methionine in their blood and tissues. The disease is 
clinically characterized by arteriosclerosis, thromboem- 
bolism, eye-lens luxation, marfanoid features, osteoporo- 
sis, and mental retardation. Therapy is based on reduction 
of the hyperhomocysteinemia by stimulation of residual 
CS activity by high levels of the cofactor pyridoxal-5'- 
phosphate [1]. About 60% of these patients respond to 
pyridoxine. In poor or non-pyridoxine responsive patients, 
treatment can be extended with folic acid, vitamin B12 or 
betaine supplementation, which enhances the homo- 
cysteine remethylation (Fig. 1) [1]. As an ultimative op- 
* Corresponding author. Fax: + 31 24 3540866. 
tion, dietary methionine restriction may be mandatory to 
reduce the blood homocysteine concentration. Despite this 
variety of therapeutical options, severely elevated homo- 
cysteine concentrations may persist in homozygotes for 
homocystinuria [2,3]. It is therefore warranted to study 
additional possibilities to reduce the blood homocysteine 
concentration i homocystinurics. 
Apart from entering the transsulfuration pathway, me- 
thionine can also be degraded via the transamination path- 
way by conversion into 4-methylthio-2-oxobutyrate 
(MTOB), followed by oxidative decarboxylation f MTOB 
to 3-methylthiopropionate (Fig. 1) [4]. In the latter reaction 
thiamine pyrophosphate, the active form of thiamine, is a 
cofactor. 
We previously demonstrated in an in vitro study that 
thiamine pyrophosphate stimulates the degradation of me- 
thionine via the transamination pathway in rat liver ho- 
0925-4439/96/$15.00 Copyright © 1996 Elsevier Science B.V. All rights reserved. 
PH S0925-4439(96)00033-6 
102 D.G. Franken et al. / Biochimica et Biophysica Acta 1317 (1996) 101-104 
mogenates [5]. The same result was obtained in human 
liver homogenates (Blom; unpublished results). In this 
study, the methionine and homocysteine-lowering effect of 
thiamine (vitamin B1) was tested in nine homozygote CS 
deficient patients. 
cysteine-lowering treatment which was also twice daily. 
Patients 3 and 4 are brothers, as well as patients 6 and 7 
(Table 1). 
2.2. Methionine and hornocysteine assay techniques 
2. Materials and methods 
2.1. Homozygotes for homocystinuria due to CS deficiency 
The criteria for selection of homozygotes for homo- 
cystinuria to enter this study were: regularly visiting our 
hospital, known with good compliance to their homo- 
cysteine-lowering treatment, prolonged elevated fasting 
homocysteine levels in blood despite homocysteine- 
lowering treatment for at least 2 yr, and at least 14 yr of 
age. Homozygosity for homocystinuria n nine patients 
was proven by hypermethioninemia, severe hyperhomocys- 
teinemia s well as a near to absent CS activity in cultured 
skin fibroblasts [3]. None of them were on a regimen of 
methionine restriction, except one (patient number 9; Table 
1). In addition to their conventional homocysteine-lowering 
treatment, six patients received 25 mg of thiamine hydro- 
chloride for 6 weeks three times daily and three patients 
twice daily (Table 1: patient number 2, 6 and 7). The latter 
three patients received only in total 50 mg thiamine hydro- 
chloride conforming with their conventional homo- 
Fasting EDTA venous blood samples were centrifuged 
immediately after puncture and stored at -20°C until 
analysis. Methionine concentrations were determined on a 
LC 2000 amino acid analyser (Biotronik Wissenschaftliche 
Ger'~ite, Munich, Germany) [6]. The total homocysteine 
concentrations (free plus protein-bound) were measured by 
a technique based on high-performance liquid chromatog- 
raphy (HPLC) and fluorescent detection [7]. 
2.3. Transamination metabolites assay techniques 
The degradation of methionine via the transamination 
pathway before and after treatment was studied by quan- 
tification in serum by the sum of the transamination 
metabolites 4-methylthio-2-oxobutyrate and the mixed 
disulfides of methanethiol (R-S-S-CH3). The blood con- 
centrations of these metabolites are low and near the 
detection limit, and because of reasons of accuracy, we 
prefer to measure the total sum of these transamination 
metabolites. This technique is based on gas chromatogra- 
phy (Packard type 429; Packard-Becker, Delft, the Nether- 
lands), supplied with a sulfur-specific flame-photometric 
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Fig. 1. Metabolism of methionine. 
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Table 1 
The fasting blood concentrations of total homocysteine, methionine, thiamine (vitamin BI) and transamination metabolites in nine cystathionine synthase 
deficient patients before (-B 1) and after (+ B 1) six weeks of thiamine treatment 
Patient Homocysteine Methionine Thiamine Transamination Therapy 
(~mol/1) (~mol / l )  nmol/1 (~mol / l )  
-B1  +BI  -B1  +BI  -B I  +B1 -B I  +BI  
1. 143 48 98 30 98 170 0.3 0.3 750B6 
2. 46 49 43 42 96 130 0.3 0.3 400B6 
3. 81 82 291 123 110 t90 0.6 0.3 750B6 
4. 82 79 94 54 120 210 bd bd 750B6 
5. 58 56 161 58 100 210 0.3 0.3 750B6 
6. 113 101 222 93 np np 0.4 0.2 500B6 
7. 82 120 139 188 np 210 bd bd 500B6 
8. 85 103 57 72 110 np 0.3 0.3 750B6 
9. 128 109 643 490 230 330 1.0 0.7 250B6 
mean ± SD 91 ± 25 83 ± 22 194 ± 127 128 ± 94 123 ± 30 207 ± 38 
normal 5 to 18 16 to 47 47 to 142 bd to 1.2 
Bl2 
FA, B12 
FA, betaine 
FA, betaine 
FA, betaine 
FA, betaine 
FA, betaine 
FA, Bl2, betaine 
FA. betaine, MPR 
Vitamin B6 (B6) was given in a daily dose in mg as indicated; folic acid (FA) was given in a daily dose of 5 mg; vitamin BI2 (B12) was given in a two 
monthly dose of 1 mg intramuscularly; betaine was given in a daily dose of 6 g; methionine poor regimen (MPR); np, not performed; bd, below level of 
detection. 
detector (Packard, model 906) [8,9]. Details of the transam- 
±nation metabolites measurement have been reported previ- 
ously [10], 
2.4. Vitamin BI measurements 
Total thiamine concentrations were determined by a 
modified procedure of the reversed-phase ion-pair HPLC 
technique described by Wielders and Mink [11]. Whole 
blood specimens are deproteinized with perchloric acid, 
followed by acid phosphatase hydrolysis of thiamine tri-, 
di- and monophosphate o thiamine, and post-column 
derivatisation of total thiamine with K3Fe(CN) 6 to 
thiochrome which is quantified fluorimetrically at excita- 
tion and emission wave lengths of 364 nm and 462 rim, 
respectively. Due to preparation steps prior to HPLC, total 
analysis time of a blood specimen takes approx. 20 h while 
the HPLC run itself, requires less than 10 rain. The lower 
limit of detection of the technique is 2.3 nmol thiamine/1 
and excellent linear standard ose-responses is obtained up 
to 400 nmol/1. At mean concentrations of 123 nmol/1, the 
precision of the technique revealed intra-assay and inter- 
assay coefficients of variation of 4.8% (9 assay runs) and 
6.8% (100 consecutive assay runs), respectively. 
2.5. Statistical analysis 
Results are given as mean_+SD. The two tailed 
Wilcoxon rank sum test was used in assessing statistical 
significance. 
was 9.0 _ 2.4 yr (range 5 to 17 yr). The mean ___ SD body 
weight was 72.3 _+ 10.6 kg (range 52.5 to 88.0 kg) and the 
mean_ SD mg thiamine dosage per kg body wt. for the 
patients was 0.90 + 0.25 mg thiamine supplementation per 
kg body weight (range 0.48 to 1.43). 
The vitamin B1 plasma concentration i the homozy- 
gotes for homocystinuria ncreased from 123 _+ 30 (mean 
_+ SD) nmol/ l  (n = 7) before thiamine treatment to 207 _+ 
38 nmol/l  (n = 7) after six weeks of thiamine treatment 
(Table 1). The fasting blood methionine concentration 
decreased from 194 + 127 #mol/1 (mean_+ SD) before 
thiamine treatment to 128 ___ 94 /xmol/1 after thiamine 
treatment (n = 9) (P  < 0.06). The mean fasting plasma 
homocysteine concentrations did not differ significantly 
before and after thiamine therapy, i.e. 91 + 25 /zmmol/1 
vs. 83 _+ 22 /~mol/l. Only one out of the nine thiamine 
treated patients showed a considerable lowering of the 
homocysteine concentration simultaneously with a major 
decrease of the methionine level (Table l, patient number 
1). Currently, this patient continues the vitamin B I supple- 
mentation for 3 yr, and the basal total homocysteine 
concentration at the most recent determination is now as 
low as 34 /~mol/1. The level of the transamination 
metabolites after thiamine did not increase in the patients. 
In fact, these levels remained low or undetectable in six 
patients and even decreased slightly in three other patients 
(Table 1). Even in the single patient with a decrease of the 
homocysteine concentration since the start with thiamine 
supplementation, the level of the transamination metabo- 
lites remained unchanged. 
3. Results 
The mean age-+-SD of all 9 homozygotes for homo- 
cystinuria was 24.4_+ 6.2 yr (range 14 to 34 yr); the 
mean _+ SD duration of homocysteine-lowering treatment 
4. Discussion 
Methionine degradation via the transamination pathway 
occurs in human but is probably of minor quantitative 
importance [10]. However, patients with hypermethionine- 
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mia due to methionine adenosyltransferase (MAT) defi- 
ciency do degrade quantitative amounts of methionine via 
the transamination pathway [ 12,16], whereas patients with 
hypermethioninemia due to cystathionine synthase (CS) 
deficiency do not, despite elevated methionine l vels [6]. 
The functional impairment of methionine transamination 
may be due to the different biochemical level of the 
blockade in the methionine metabolism or due to the 
treatment of CS deficient patients by pharmacological 
amounts of vitamins, in particulary pyridoxine [6]. The 
present study was performed because of the theoretical 
possibility to lower homocysteine concentrations by en- 
hancement of methionine degradation via the transamina- 
tion pathway in CS deficient patients. 
Previous in vitro studies with rats [5] and human ho- 
mogenates [Blom H, unpublished ata] have shown that 
thiamine pyrophosphate stimulated the methionine degra- 
dation via the transamination pathway 2.5 fold. This active 
form of thiamine is a cofactor of the branched-chain 
2-oxo-acid dehydrogenase complex which catalyses the 
oxydative decarboxylation of 4-methylthio-2-oxobutyrate 
into 3-methylthiopropionate [13,14]. This decarboxylation 
is supposed to be the rate-limiting reaction in the transami- 
nation of methionine [4]. 
Thiamine was administered in 9 homozygotes for ho- 
mocystinuria in addition to their conventional homo- 
cysteine-lowering treatment. All these patients except one, 
demonstrated virtually unchanged levels of plasma homo- 
cysteine and serum transamination metabolites, despite the 
observed reduction of their methionine concentrations. 
Very recently, it has been reported that transamination in 
hypermethioninemic children is abnormally elevated only 
when plasma methionine l vels exceeded 300 or 350 /~M 
[15,16]. In the present study, only patient number 9 (Table 
1) has a methionine l vel above this methionine l vel, and 
indeed, his transamination metabolites were higher than in 
the other 8 investigated homozygotes for homocystinuria, 
but still much lower than those of MAT deficient patients 
with comparable methionine levels [6,16]. But even his 
serum transamination metabolites concentration did not 
increase after the supplementation of thiamine. 
We have no straightforward explanation for the reduc- 
tion of the methionine concentration i  most of the homo- 
cystinuric patients due to thiamine supplementation. The 
flux of methionine degradation through the transamination 
pathway can be decreased by glutamine, glutamic acid, 
alanine or leucine in the presence of 4-methylthio-2- 
oxobutyrate [17]. Thiamine is involved as a cofactor in the 
oxydative decarboxylation i the degradation of many 
amino acids, including the four mentioned above. Theoret- 
ically, thiamine administration may decrease the levels of 
glutamine, glutamic acid, alanine and leucine, and indi- 
rectly stimulate methionine degradation via its transamina- 
tion pathway. However, the serum transamination metabo- 
lites of methionine were not elevated during thiamine 
administration. But, the levels of these metabolites may 
have remained unchanged despite an increased methionine 
degradation through the transamination pathway. Studies 
using stable isotopes of methionine could clarify this mat- 
ter. 
In conclusion, orally administered thiamine lowered the 
homocysteine l vel in only one out of the nine homo- 
cystinuric patients studied despite the reduction of the 
methionine concentration in most patients. Therefore, vita- 
min B 1 appears to be only a minor alternative option for 
homocysteine-lowering treatment ext to vitamin B6, B I2, 
folic acid, and betaine in homozygotes for homocystinuria. 
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